PreprintConcept PaperVersion 1Preserved in Portico This version is not peer-reviewed
SALIQ in Rhabdomyosarcoma: A Repurposed Multidrug Regimen to Augment Standard Treatments by Adding Simvastatin, All Trans Retinoic Acid, Lithium, Itraconazole, and Quercetin
Version 1
: Received: 28 September 2023 / Approved: 28 September 2023 / Online: 28 September 2023 (07:39:00 CEST)
How to cite:
Kast, R.E.; Zaghloul, M.S.; Sardi, I.; Halatsch, M. SALIQ in Rhabdomyosarcoma: A Repurposed Multidrug Regimen to Augment Standard Treatments by Adding Simvastatin, All Trans Retinoic Acid, Lithium, Itraconazole, and Quercetin. Preprints2023, 2023091957. https://doi.org/10.20944/preprints202309.1957.v1
Kast, R.E.; Zaghloul, M.S.; Sardi, I.; Halatsch, M. SALIQ in Rhabdomyosarcoma: A Repurposed Multidrug Regimen to Augment Standard Treatments by Adding Simvastatin, All Trans Retinoic Acid, Lithium, Itraconazole, and Quercetin. Preprints 2023, 2023091957. https://doi.org/10.20944/preprints202309.1957.v1
Kast, R.E.; Zaghloul, M.S.; Sardi, I.; Halatsch, M. SALIQ in Rhabdomyosarcoma: A Repurposed Multidrug Regimen to Augment Standard Treatments by Adding Simvastatin, All Trans Retinoic Acid, Lithium, Itraconazole, and Quercetin. Preprints2023, 2023091957. https://doi.org/10.20944/preprints202309.1957.v1
APA Style
Kast, R.E., Zaghloul, M.S., Sardi, I., & Halatsch, M. (2023). SALIQ in Rhabdomyosarcoma: A Repurposed Multidrug Regimen to Augment Standard Treatments by Adding Simvastatin, All Trans Retinoic Acid, Lithium, Itraconazole, and Quercetin. Preprints. https://doi.org/10.20944/preprints202309.1957.v1
Chicago/Turabian Style
Kast, R.E., Iacopo Sardi and Marc-Eric Halatsch. 2023 "SALIQ in Rhabdomyosarcoma: A Repurposed Multidrug Regimen to Augment Standard Treatments by Adding Simvastatin, All Trans Retinoic Acid, Lithium, Itraconazole, and Quercetin" Preprints. https://doi.org/10.20944/preprints202309.1957.v1
Abstract
Rhabdomyosarcoma is a cancer arising from arrested myogenic differentiation, seen mainly in children or adolescents. Metastatic rhabdomyosarcoma is often fatal even with aggressive cytotoxic chemotherapies, surgery, and irradiation. SALIQ is an acronym for a multidrug augmentation regimen designed as an adjunct to current rhabdomyosarcoma chemotherapies. SALIQ uses five common non-oncology drugs, repurposed from general medicine use, to promote malignant clone maturation and inhibit rhabdomyosarcoma growth. The five drugs are: the cholesterol lowering drug simvastatin, the acne medicine tretinoin (ATRA), the psychiatric drug lithium carbonate, the antifungal drug itraconazole, and the food supplement quercetin. All five drugs are in common use for non-cancer conditions, are cheap, have an eminently safe side effect profile, and all five have preclinical evidence and good rationale for inhibiting rhabdomyosarcoma growth.
Keywords
chemotherapy; repurposed drugs; rhabdomyosarcoma
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
